Objective: To describe the course, complications, and prognosis of Ullrich congenital muscular dystrophy (UCMD), with special reference to life-changing events, including loss of ambulation, respiratory insufficiency, and death.
pore (PTP) dysfunction, and increased muscle apoptosis was established. 8 In an animal model of UCMD, the mitochondrial damage could be prevented with cyclosporin A, an inhibitor of mitochondrial PTP. 9 More recently, a pilot trial conducted in children with UCMD reported that cyclosporin A decreased muscle apoptosis. 10 Although cyclosporin toxicity limits its prolonged use in children, other less toxic drugs are now being considered for therapeutic intervention in UCMD.
Although better overall respiratory management has improved survival, there is currently no specific treatment for UCMD. There is therefore a compelling need to define the natural history of the disease to be able to provide anticipatory care plans and prepare for future clinical trials. In this study, we aimed to describe the long-term outcome of a relatively large cohort of patients with UCMD, followed up at our center, in which long-term longitudinal follow-up data were available. We concentrated on life-changing events such as loss of independent ambulation and respiratory failure.
METHODS Patients. We reviewed the case notes of patients with UCMD, followed up at the Dubowitz Neuromuscular Centre, London, UK, from whom we had follow-up data over a 10-year period (from 1977 to 2007) . To better illustrate the course of the disease, we have included patients aged 15 years or older at the last clinical attendance as well as those born in the same period who died during the course of follow-up. The diagnosis of UCMD was made in patients with 1) distal joint hyperlaxity, proximal contractures and weakness, respiratory impairment, normal intelligence, and 2) genetic confirmation of COL6A1, COL6A2, or COL6A3 mutations.
We collected the following variables: presenting symptoms and age at onset, maximum motor functional ability, wheelchair dependency and age at loss of ambulation, scoliosis severity, contracture distribution and severity, need for and age at initiation of noninvasive ventilation (NIV), feeding difficulties and need for gastrostomy, skin abnormalities, creatine kinase (CK) values, muscle or fibroblast culture pathology, and genetic reports. As part of their yearly medical follow-up visits, patients had a forced vital capacity (FVC) measurement and a detailed physiotherapy assessment. We were therefore able to review longitudinal data on FVC values, muscle power graded according to the Medical Research Council scale, motor function graded according to the Hammersmith motor ability scale (MAS), and joint ranges. 11 Five patients have been previously described in brief (patients 2, 3, 5, 10, and 11; table 1). 5 This study was approved by the Hammersmith Hospital Trust Ethics Committee (project 00/580).
Collagen VI immunolabeling and genetic analysis. The immunolabeling and genetic analysis methods have been previously described. 12, 13 Statistical analysis. Descriptive statistics, regression analysis, and Kaplan-Meier curves were performed with the use of SPSS version 15.
RESULTS
We analyzed data on 13 patients with UCMD, including 2 patients who died of respiratory failure at the ages of 10.8 and 15.1 years (patients 12 and 13; table 1). The mean age at the last medical visit was 19.5 years (SD 5.5 years), and the mean duration of follow-up was 14.4 years (SD 6.9 years). All patients had normal cognitive abilities and cardiac function.
Family history. Three patients were born from consanguineous parents (patients 6, 7, and 9; table 1). Patients 6 and 9 were cousins, whereas patients 2 and 3 were twin sisters (table 1).
Onset of symptoms. The mean age at onset of symptoms was 12 months (SD 14 months). Six patients (46.2%) had a congenital presentation with variable combinations of congenital hip dislocation (n ϭ 2), hypotonia (n ϭ 3), contractures (n ϭ 4), torticollis (n ϭ 2), scoliosis (n ϭ 1), and feeding difficulties necessitating transient nasogastric tube feeding (n ϭ 2) (table 1). The remaining 7 patients (53.8%) presented between ages 1 and 3 years. The most common presentations in these patients were delayed motor milestones (n ϭ 11) and proximal weakness (frequent falls, difficulty running and climbing) (n ϭ 4) (table 1). Tiptoe gait was the initial symptom in 1 patient (table 1) .
Muscle weakness. The distribution of muscle weakness was predominantly proximal and axial. Neck flexors were weak in all patients. Some degree of facial weakness was observed in 4 patients (30.8%) (table 1).
Motor functional ability. Independent ambulation (defined as the ability to walk at least 10 meters unassisted) was acquired in 8 patients (61.5%) at a mean age of 1.7 years (SD 0.8 years). The other 5 patients (38.5%) never acquired independent ambulation. They were, however, able to walk with support (walkers or knee-ankle-foot orthoses) at a mean age of 3.6 years (SD 1.4 years). None of the patients ever ran (table 1) .
At the last medical visit, 9 patients (69.2%) were constant wheelchair users (figure 1). The mean age at loss of independent ambulation was 10.7 years (SD 4.8 years), whereas the mean age at constant wheelchair dependency was 11.1 years (SD 4.8 years). Among the patients who were not wheelchair dependent at the last visit, 3 could still walk independently indoors for at least 5 steps, whereas 1 patient could only manage a few steps indoors with support. The maximum MAS in the ambulant patients (normal value ϭ 40) ranged from 12 to 30, with a mean of 24 (SD 6). 11 The mean MAS improved between ages 5 and 8 years and then gradually declined at a mean rate of 2 points yearly (SD 2 points) in the ensuing years.
Contractures. Contractures were present at birth in only 4 patients, 1 with isolated bilateral talipes and 3 with multiple joint contractures (table 1) . Torticollis was seen in 2 patients (table 1). In the first decade of life, all patients developed multiple joint flexion contractures. Long finger flexor contractures were present in 11 patients (data missing for 2 patients) (table 1). Other common joints affected by contractures were the elbows (n ϭ 9), ankles (n ϭ 8), knees (n ϭ 7), and hamstrings (n ϭ 5). Surgical release of the Achilles tendons (TAs) was performed in 4 patients. One patient was treated with serial casting. Despite the recurrence of contractures, none of the patients underwent repeated surgical release of the TAs or serial casting because of the poor functional achievements of the patients. Surgery of other joints was less frequently performed: hip flexors (n ϭ 1) and iliotibial bands (n ϭ 1).
Spine. Scoliosis developed in 12 patients (92.3%) at a mean age of 6.5 years (SD 4.2 years) (table 1). Congenital scoliosis, documented in only 1 patient (patient 10; table 1), was not associated with a more severe course. The onset of scoliosis preceded loss of ambulation in all patients but one, by a mean of 7.0 years (SD 4.3 years) (table 1). Scoliosis surgery was performed in 5 patients (38.5%) at a mean age of 11.2 years (SD 2.0 years) (patients 2, 3, 5, 10, and 11). The mean Cobb angle measurement at the time of scoliosis surgery was 69°( SD 49°). Kyphosis was documented in 6 patients (46.2%), of whom 1 did not have a concomitant scoliosis (table 1). Kyphosis was treated conservatively without bracing or surgery. Spine rigidity was noted in all but 1 patient (92.3%) (table 1).
Respiratory function.
The FVC values were abnormal, i.e., below 80% predicted, in all patients from age 6 years (figure 2). This was the earliest age at which the FVC measurements were regularly performed. There was a progressive decline of the mean FVC (% predicted) at a mean rate of 2.6% (SD 4.1%) yearly (figure 2). The FVC (% predicted) declined by 6.6% (SD 1.9%) yearly from age 6 to 10 years, by 0.4% (SD 3.0%) yearly from 11 to 15 years, and by 2.4% (SD 4.1%) yearly from 16 to 20 years.
At the last medical visit, 9 patients (69.2%) were established on nocturnal NIV (table 1 and figure 3 ). The mean age at initiation of nocturnal NIV was After the introduction of NIV, FVC improvement (defined as 10% predicted or more) was observed in only 1 patient (patient 6, in whom FVC improved by 10% in the 2 years after NIV initiation).
Respiratory insufficiency followed loss of ambulation in 61.5% of patients (n ϭ 8) (table 1) .
Scoliosis surgery was not associated with an improvement of pulmonary function. 3 years) . These patients' weights remained under the third percentile, despite the use of a gastrostomy and regular feeding supplementation.
Skin abnormalities. Skin abnormalities were reported in 100% (n ϭ 8) of the patients for whom complete data were available. Follicular hyperkeratosis was observed in 8 patients, and abnormal scarring with keloid formation was observed in 3 (table 1) .
Creatine kinase. The mean serum CK was 298 IU/L (SD 192 IU/L) (normal values 0 -200 IU/L). The levels ranged from normal to 3 times the upper limit of normal (table 2) .
Collagen VI immunolabeling and genetic analysis. Fibroblast collagen VI immunolabeling was abnormal in all patients in whom it was examined (table 2) . Muscle collagen VI immunolabeling was absent in 1 patient, reduced in 4, and normal in 2 (table 2) . Double labeling with collagen IV or perlecan was not performed in these 2 patients' original muscle biopsies. Muscle samples are not available for further detailed double immunolabeling studies. Eight patients had a de novo dominant mutation, whereas the remaining 5 patients had recessive mutations (4 homozygous and 1 compound heterozygous) (table 2) . DISCUSSION UCMD is one of the most common CMD variants. The presenting symptoms, main Table 2 Laboratory tests clinical features, and complications of this condition have been previously described. 5 However, the rate of disease progression and its correlation with severity of presenting symptoms are not well described. In this study, we aimed to provide natural history data on the disease progression beyond childhood in a relatively large population of patients. Our study included 13 patients with a mean age of 19.5 years.
The presenting features and age at presentation in these patients did not always correlate with the motor and respiratory function at last follow-up. In some patients, despite a severe congenital presentation with contractures, ambulation was maintained late into the second decade of life, and respiratory support was not required at that time. By contrast, other patients presenting later with delayed motor milestones lost the ability to walk after a few years and experienced respiratory failure in the first decade of life.
Most (61.5%) of our patients acquired independent ambulation, whereas the rest (38.5%) achieved ambulation only with support. Maximum functional outcome did not correlate with age at onset of symptoms or the results of collagen VI immunolabeling or type of genetic mutations. Of the 8 patients who had acquired independent ambulation, only 1 still walks independently, whereas 3 manage a few steps indoors. The age at constant wheelchair dependency was variable, from 3.5 to 19 years (mean 11.1 years). The maximum MAS scores, which represent the motor function and their decline rates were not homogeneous between patients. Multiple factors are likely to explain such variability in disease progression, including the distribution and severity of muscle weakness, progression of contractures, respiratory function, growth, and weight gain.
Scoliosis developed in all patients except one, who died at 10.8 years, before the pubertal growth spurt. The age at onset was between birth and 13.8 years, preceding the loss of ambulation in all patients but one. This course is dissimilar to Duchenne muscular dystrophy (DMD), in which scoliosis predominantly progresses after loss of ambulation. 14 In UCMD, the early onset of scoliosis, often present at birth, probably reflects a combination of axial weakness and contractures of the vertebral joints. Surgery was generally performed around the age of NIV introduction.
Regarding respiratory function, we have found that the FVC values were universally abnormal as early as age 6 years. The mean rate of deterioration of FVC (% predicted) was 2.6% yearly. The decline in respiratory function was not homogeneous throughout the study period, being maximal in the first decade of life and slowing down from the early teens. All patients but 2 currently have respiratory insufficiency and require NIV. The age at NIV initiation was variable, from 10.8 to 25.3 years (mean 14.3 years). One patient eventually required 12 hours of respiratory support. Two patients died from respiratory failure at 10.8 and 15.1 years, having declined ventilation. Interestingly, respiratory insufficiency was observed in nearly half of the patients who were ambulant (with or without support). This again differs from DMD, in which respiratory failure invariably follows loss of ambulation. 15 However, similar to what is described in DMD, the lack of intervention in patients in respiratory insufficiency is relatively rapidly followed by death. One patient who did not wish to have NIV died within 9 months from when abnormal sleep study results were demonstrated. Our data confirm previous descriptions on the occurrence of respiratory insufficiency in UCMD and indicate that monitoring respiratory function is crucial in these patients, with major implications for morbidity and mortality. In this cohort (mean age 19.5 years), 15% of patients had died, in contrast to the series of Nonaka et al. in 1981 (mean age 11.6 years), in which 50% had died. 16 A significant number of individuals had feeding difficulties and were underweight. Almost one-third of them underwent gastrostomy at a mean age of 13.1 years. The procedure was well tolerated. However, it was not accompanied by a substantial improvement in weight gain despite appropriate caloric supplementation. Whether earlier intervention would have resulted in a better weight gain remains to be established.
Collagen VI immunolabeling was abnormal in fibroblast culture in all patients studied. It was abnormal in muscle biopsies of all patients but 2. These 2 muscle biopsies were studied before the double labeling studies with collagen IV or perlecan, now considered to be the gold standard for the histopathologic diagnosis, were available. 12 Unfortunately, we do not have more frozen material from these 2 patients. As from previous studies, we did not observe a correlation between the extent of collagen VI reduction and the clinical phenotype. 12 Collagen VI immunolabeling was absent in 1 patient (recessive mutation), but his phenotype was not more severe than that observed in patients with de novo dominant mutations and residual expression of the protein. 13 More than half of our patients had a de novo dominant mutation, similarly to what was reported by others. 13 Two patients had a heterozygous mutation in the splice donor site of COL6A3 intron 16, believed to represent a common mutation in UCMD. Two patients (patients 4 and 13) had a mutation in COL6A1 exon10, which was previously reported in patients with a mild phenotype of UCMD and a severe form of Bethlem myopathy. 17 Patient 4 is not yet wheelchair dependent or ventilated at 18 years, whereas patient 13 had a more severe course, losing ambulation at age 10 years and dying at 15 years after a fracture. Finally, we report 2 new mutations in COL6A2 (exon3 c.536GϾA p.Arg179Gln [patient 5, heterozygous] and exon28 c.2839 2850del p.Leu947 Gly950del [patient 7, homozygous]). Patient 5 only walked with support until age 17.3 years but was not ventilated then. Patient 7 still walks with support at age 26 years and has been on NIV since age 19.7 years.
While future prospective studies will help to clarify further the natural history of UCMD, the data presented in this study should be of help to investigators involved in the design of therapeutic trials in this condition. 
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